Data from the first analysis of the The Prostate Cancer Registry was presented recently at the European Cancer Congress (ECC) in Vienna, Austria and found that there is a high incidence of co-morbidity in the patient group.
The registry, funded by Janssen EMEA, is the first and largest prospective study of patients with metastatic castration-resistant prostate cancer (mCRPC) in Europe. It aims to provide real world data to help improve the quality of care for men with mCRPC.
With the aim of enrolling a total of 3,000 patients, to date more than 2,500 mCRPC patients from 192 centres in 16 European countries have been enrolled. Patients in the study will be followed for up to three years. By collecting real world data from such a large patient population in both oncology and urology clinics, the registry has the capacity to address key medical and scientific questions concerning the optimal care of people with mCRPC in routine practice, such as treatment sequencing, treatment outcomes, impact on quality of life, medical resource utilisation and patient safety.
Dr Simon Chowdhury, Guy’s Hospital, London, said: “Whilst the advent of new, more effective treatments has benefited many patients, for doctors, increased treatment options raise more questions about which are the right treatments to give individual patients and in what order. The registry follows patients we see in everyday practice: patients with multiple co-morbidities such as heart disease and diabetes. The size and scope of the registry will allow us to analyse large-scale datasets to better understand how we can best utilise the various therapeutic options and tailor treatment to our patients’ individual needs. As the database matures, we can expect to keep building our knowledge on contemporary mCPRC management in daily practice.”
The first analysis presented at ECC 2015 indicates an enrollment of a broad range of patients with complex clinical presentations, reflecting the real-world nature of the population studied. Patients in the study have a mean age of 71.5 years and a high incidence of comorbidities (62.8%), the most common being cardiovascular disease (54.9%) and hypertension (44.6%). 79.2% of the patients enrolled were prescribed concomitant medications. 41.4% of patients had previously received chemotherapy and 58.6% were chemotherapy-naïve at enrolment.
Further analyses and data releases are being planned for early 2016. Prostate cancer is the most commonly diagnosed cancer in men, with over 400,000 new cases diagnosed in Europe each year.